SMPD1 and central nervous system cancer: Interestingly, the survival analysis revealed that the overall survival of patients with glioma (WHO grades II–IV) with a more than 2-fold increase of ASM was reduced in comparison with patients with intermediate expression, but this analysis is limited by the fact that only 7 patients showed increased levels of ASM mRNA (Fig. 1B).